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Chronic infection with the gastric bacterial pathogen Helicobacter pylori causes gastritis
and predisposes carriers to a high risk of developing gastric and duodenal ulcers, gastric
cancer, and gastric lymphoma, but has also recently been shown to protect against certain
allergic and chronic inﬂammatory disorders. The immunomodulatory properties that allow
the bacteria to persist for decades in infected individuals in the face of a vigorous, yet
ultimately non-protective, innate, and adaptive immune response may at the same time
confer protection against allergies, asthma, and inﬂammatory bowel diseases. Experimen-
tal evidence from mouse models suggests that H. pylori has evolved to skew the adaptive
immune response toward immune tolerance rather than immunity, which promotes per-
sistent infection on the one hand, and inhibits auto-aggressive and allergicT-cell responses
on the other. Regulatory T-cells mediating peripheral immune tolerance have emerged as
key cellular players in facilitating persistent infection as well as protection from allergies, in
both observational studies in humans and experimental work in mice. Recent data suggest
that H. pylori actively targets dendritic cells to promote tolerance induction. The ﬁndings
discussed in this review raise the possibility of harnessing the immunomodulatory prop-
erties of H. pylori for the prevention and treatment of allergic and auto-immune diseases,
and also provide new insights relevant for H. pylori -speciﬁc vaccine development.
Keywords: Helicobacter immunomodulation, asthma and allergies, dendritic cells and regulatoryT-cells, immune
tolerance
INTRODUCTION
Helicobacter pylori is the most common bacterial infection in
humans worldwide. The bacteria possess the remarkable ability
to persist in infected individuals for many decades and have inti-
mately co-existed with humans at least since they ﬁrst migrated
out of EastAfrica approximately 60000 years ago (Linz et al., 2007).
During this long period of co-evolution, the bacteria have acquired
traits that allow them to evade and subvert both innate and adap-
tive branches of the immune system to ensure their persistence
in the face of a vigorous, yet ultimately non-protective, local and
systemic immune response (Muller et al., 2011). The evolution-
ary costs possibly associated with the gastric pathology induced
by chronic H. pylori infection have been proposed to be offset
by potential beneﬁts and a selective advantage for human car-
riers (Blaser and Atherton, 2004). Indeed, epidemiological and
experimental data now point to a strong protective effect of H.
pylori infection on the development of many extra-gastric dis-
eases, including gastroesophageal reﬂux disease and its associated
sequels (Vaezi et al., 2000; Islami and Kamangar, 2008; Whiteman
et al., 2010), childhood asthma and allergy (Chen and Blaser, 2008;
Amberbir et al., 2011), and certain metabolic disorders (Osawa
et al., 2005; Mera et al., 2006). The epidemiological and exper-
imental evidence for possible protective properties of H. pylori
infection, as well as the mechanistic basis underlying these effects,
are the subject of this review.
H. PYLORI PROTECTS AGAINST ALLERGIC ASTHMA AND
OTHER ATOPIC DISEASES
THE PATHOGENESIS OF ASTHMA
In allergic asthma, genetically susceptible individuals respond
to environmental allergens with inappropriate T-cell-mediated
immune responses, leading to chronic obstruction of the air-
ways. Allergic asthma is characterized by the accumulation of
inﬂammatory inﬁltrates in the lung, airway hyper-responsiveness
to a variety of speciﬁc and non-speciﬁc stimuli, increased
serum immunoglobulin E (IgE) levels, and mucus hypersecretion.
Chronic inﬂammation further leads to structural changes (airway
remodeling) with collagen deposits, hyperplasia, and thickening
of the airway wall. In asthmatic patients, allergic episodes trigger
the bronchoalveolar inﬁltration of various immune cell popula-
tions, mostly eosinophils, mast cells, and activated CD4+ T-cells.
Effector T-helper 2 (Th2) cells play a central role in orchestrating
the immune response to allergens by releasing cytokines that trig-
ger the predominant features of asthma (Robinson et al., 1992):
the secretion of IL-4 and IL-13 contributes to B-cell production
of IgE (Wills-Karp et al., 1998; Bacharier and Geha, 2000), the
release of IL-5 drives eosinophilic inﬂammation (Wang et al., 1989;
Rosenberg et al., 2007), and IL-9 stimulates mast cell prolifera-
tion (Renauld et al., 1995). The action of IL-4 and IL-13 on lung
epithelia further induces goblet cell metaplasia, whereas IL-13 act-
ing on smooth muscle cells promotes the development of airway
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hyper-responsiveness (Wills-Karp et al., 1998). Recently, other
subsets of T-helper cells have been linked to asthma pathogen-
esis, including Th9 (Shimbara et al., 2000; Erpenbeck et al., 2003),
Th25 (Tamachi et al., 2006; Ballantyne et al., 2007), and Th22
cells (Nakagome et al., 2011). A subset of lung-inﬁltrating T-cells
known asTh17 cells has been described to account for neutrophilic
airway inﬂammation, but also for enhanced Th2-cell-mediated
eosinophilic airway inﬂammation (Wakashin et al., 2008). IL-17
secretion by both Th17 cells and eosinophils was further found to
be increased in asthmatic patients (Molet et al., 2001). Although
asthma is generally considered to be an adaptive immune disor-
der, the innate arm of the immune system also contributes to the
pathology through the production of pro-inﬂammatory media-
tors by bronchial epithelial cells (Kauffman et al., 2006), mast
cells (Amin et al., 2005), basophils (Ono et al., 2010), natural
killer T (NKT) cells (Akbari et al., 2003), and dendritic cells (DC;
Lambrecht et al., 2000).
There is now ample evidence that a variety of suppressive and
regulatory mechanisms are crucially involved in preventing the
activation of potentially harmful effector responses in the lungs
of healthy individuals (Ray et al., 2010). This task is predomi-
nantly accomplished by CD4+CD25+ regulatory T-cells (Tregs)
that either develop in the thymus (natural Tregs) or are induced in
the periphery in response to speciﬁc antigens (adaptive or induced
Tregs). Tregs can suppress pathogenic T-cell responses through
direct contact with their target cells or via the release of anti-
inﬂammatory cytokines such as IL-10 and transforming growth
factor beta (TGF-β). Both CD25hi (Curotto de Lafaille et al.,
2008) and IL-10-producing Tregs (Akdis et al., 2004) have been
implicated in preventing Th2 responses to allergens. Peripheral
blood-derived CD4+CD25+ Treg subsets of healthy individuals
indeed inhibit the proliferation and cytokine production of their
allergen-responsive CD4+CD25− effector counterparts in vitro.
In contrast, this ability was reduced in Treg subsets of allergic
individuals, suggesting that effective suppression of pathogenic
Th2 responses might be defective or overridden in patients with
allergic diseases (Robinson, 2009). In bronchoalveolar lavage ﬂuid
(BALF) from asthmatic children, both the percentage and the
suppressive capacity of Tregs were reduced compared to healthy
control individuals (Kay, 2001). In a mouse model of ovalbumin-
induced airway inﬂammation, the transfer of ovalbumin-speciﬁc
Tregs could prevent or reverse the development of airway hyper-
responsiveness and Th2 immune responses in an IL-10-dependent
manner (Boudousquie et al., 2009). Overall, these ﬁndings sug-
gest that functional Tregs of healthy individuals shift allergen-
speciﬁc immune responses toward tolerance, thereby preventing
the development of asthma and other allergic disorders.
HELICOBACTER INFECTION IS INVERSELY CORRELATED WITH
ALLERGIC ASTHMA IN HUMANS
Many atopic individuals never develop allergic disease manifesta-
tions in their lifetime, suggesting that the genetic background acts
synergistically with environmental factors to determine individ-
ual allergy susceptibility. The inﬂuence of environmental factors is
drastically illustrated by the alarming increase of asthma and asso-
ciated allergic disease incidence in Western societies over the last
decades, especially among children (Eder et al., 2006). A plausible
explanation has been formulated in the “hygiene hypothesis,”
which postulates a causal inverse relationship between allergies
andpediatric infectious diseases (Strachan,1989).At the immuno-
logical level, this hypothesis proposes that early life exposure to
microbial antigens is required for the normal maturation of the
immune system and the generation of protective regulatory T-cell
responses. This notion has recently been revisited by Blaser and
Falkow (2009), who suggest that the speciﬁc loss of our ancestral
indigenous microbiota due to modern hygienic practices and the
widespread use of antibiotics, rather than a general decline in arbi-
trary childhood infections, is causally associatedwith the epidemic
increase of asthma and other allergic diseases.
In experimental models of airway inﬂammation, several
viral and parasitic pathogens, including inﬂuenza viruses and
helminths, have been implicated in protection against asthma and
allergy (Wilson et al., 2005; Kitagaki et al., 2006). In addition,
the role of H. pylori as a protective agent against atopic disor-
ders has been suggested by numerous cross-sectional (Matricardi
et al., 2000; Kosunen et al., 2002; Linneberg et al., 2003; Jarvis
et al., 2004; Radon et al., 2004; von Hertzen et al., 2006; Herbarth
et al., 2007; Janson et al., 2007; Shiotani et al., 2008) and case–
control studies (Bodner et al., 2000; Matricardi et al., 2000; Tsang
et al., 2000; Jun et al., 2005). McCune and colleges have reported
that individuals carrying H. pylori were 30% less likely to have
concomitant allergic conditions, including asthma, eczema, and
allergic rhinitis (McCune et al., 2003). Several independent stud-
ies have further suggested more pronounced protective effects of
H. pylori in children and in individuals with early onset asthma
(Chen and Blaser, 2007, 2008; Amberbir et al., 2011) and in CagA-
seropositive individuals (Chen and Blaser, 2007; Reibman et al.,
2008).
ASTHMA PROTECTION CONFERRED BY H. PYLORI IS MEDIATED BY
REGULATORY T-CELLS
We have recently reported that experimental H. pylori infection
prevents allergic asthma in a mouse model of ovalbumin- or house
dust mite-induced airway inﬂammation (Arnold et al., 2011a).
Infected mice were efﬁciently protected against allergen-induced
airway hyper-responsiveness, tissue inﬂammation, and goblet cell
metaplasia, and exhibited reduced pulmonary and bronchoalveo-
lar inﬁltration with eosinophils, Th2 cells, and Th17 cells (Arnold
et al., 2011a). The protection against asthma could be attributed
to H. pylori-induced, highly suppressive Tregs, which accumulate
in the lungs of infected mice and block pathogenic effector T-
cell responses (Figure 1). The depletion of CD4+CD25+ Tregs
by systemic administration of a CD25-neutralizing antibody led
to enhanced pulmonary inﬂammation and abrogated the char-
acteristic T-cell hypo-responsiveness to ovalbumin in infected
mice. The adoptive transfer of Tregs puriﬁed from the mesenteric
lymph nodes of infected but not naïve donors was further sufﬁ-
cient to transfer protection to uninfected recipients (Arnold et al.,
2011a). In addition, H. pylori-infected animals were characterized
by lung-inﬁltrating semi-mature DC, which might suggest that
Tregs generatedduring infectionhave the ability to inﬂuence extra-
gastric immune responses by retaining DCs in a semi-mature state
(Figure 1). An analogous mechanism was recently proposed by
Onishi et al. (2008) who found that FoxP3+ Tregs form aggregates
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on DCs to actively down-regulate their co-stimulatory molecules
CD80 and CD86, thus competing with naïve T-cells for access to
DCs and limiting their ability to activate effector T-cell responses.
Our ﬁnding of the accumulation of Tregs and semi-mature DCs in
the lungs of infected, but not asthmatic mice (Arnold et al., 2011a)
is in line with this model of asthma prevention (summarized
schematically in Figure 1).
ASTHMA PROTECTION CONFERRED BY H. PYLORI IS LINKED TO THE
EXPRESSION OF SPECIFIC VIRULENCE FACTORS AND IS MOST
PRONOUNCED IN YOUNG INDIVIDUALS
Although a negative association between CagA-positive H. pylori
infection status and allergic disease manifestations has been sug-
gested (Chen and Blaser, 2007), protection conferred by H. pylori
infection in our model was not linked to the expression of a
functional type IV secretion system (Arnold et al., 2011a). Inter-
estingly, the mucosal or systemic administration of the H. pylori
neutrophil-activating protein (HP-NAP) in a therapeutic model
of asthma was shown to inhibit bronchial inﬂammation through
agonistic ligation of toll-like receptor 2 (TLR2; Codolo et al.,
2008). HP-NAP delivery reduced lung eosinophilia in response
to repeated ovalbumin challenge and decreased the production of
IL-4, IL-5, and GM–CSF in the bronchioalveolar ﬂuid (Codolo
et al., 2008). In H. pylori-infected individuals, stimulation of lam-
ina propria lymphocytes with HP-NAP further increased IL-10
production compared to uninfected controls, while reducing the
proliferative and IFN-γ responses of stimulated PBMC (Windle
et al., 2005). Because IL-10 is a key cytokine in the resolution
of asthmatic inﬂammation (Xystrakis et al., 2006; Ogawa et al.,
2008), this raises the possibility that speciﬁc H. pylori virulence
FIGURE 1 | Schematic representation of the current model of H.
pylori -induced immune tolerance and asthma protection. Tolerogenic
dendritic cells and H. pylori -induced regulatory T-cells act in concert to
prevent adaptive Th1/Th17-driven immunity to the infection and to inhibit
allergen-speciﬁc Th2 responses. In chronically infected humans, H. pylori
resides exclusively in the gastric mucosa, where it is presumably
encountered and detected by tissue-resident DC populations extending
dendrites into the gastric lumen. H. pylori -experienced DCs migrate to the
gut-draining mesenteric lymph nodes, where they act as potent inducers
of TGF-β-dependent FoxP3+ regulatory T-cells, but fail to prime H.
pylori -speciﬁc Th1 andTh17 responses. InducedTregs may further
perpetuate the tolerogenic effects of H. pylori -experienced DCs by
retaining mesenteric lymph node DCs in a semi-mature state and by
directly suppressing H. pylori -speciﬁc gastric Th1 andTh17 responses,
thereby protecting the host from excessive gastric immunopathology.
Newly inducedTregs further migrate to the lung, where they suppress
allergen-speciﬁc Th2 andTh17 responses involved in the pathogenesis of
asthma. The generation of allergic T-cell responses may be blocked either
through the tolerogenic effects of Tregs on DCs (retaining DCs in a
semi-mature state) or directly through suppression of Th2 andTh17
responses via Treg/T-effector cell contact or via soluble cytokines, in
particular IL-10. The ultimate outcome of gastric H. pylori infection on the
allergen-challenged lung is reduced eosinophilia, mucus production and
airway hyper-responsiveness. The involvement of the tracheal lymph
nodes in H. pylori -induced asthma suppression is likely, but currently not
well understood.
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factors promote protection against allergic diseases by stimulating
the Treg-speciﬁc production of IL-10.
Early onset asthma in children and adolescents is rare in the
H. pylori-infected population (Chen and Blaser, 2008). H. pylori-
infected children are known topreferentially launchTreg responses
to the pathogen (Harris et al., 2008), which may account for the
particularly beneﬁcial effects of H. pylori in this population. Sim-
ilarly, experimental H. pylori infection induces a continuum of
protection against airway inﬂammation that is negatively corre-
lated with age at the time of infection. Protection was most evi-
dent in neonatally infected mice, which develop H. pylori-speciﬁc
immunological tolerance mediated by long-lived, inducible Tregs
(Arnold et al., 2011b). Because the neonatal period of life is a
uniquedevelopmental stage inwhich immune responses are highly
plastic and inherently biased toward tolerance, Tregs generated
during the ﬁrst weeks and months of life are thought to differ
qualitatively in their suppressive potential compared to their adult
counterparts. Indeed, murine neonatal CD4+ T-cells were shown
to intrinsically differentiate intoCD4+FoxP3+ Tregs in response to
TCR stimulation and TGF-β signals (Wang et al., 2010). They fur-
ther stably express high levels of FoxP3, which renders them par-
ticularly suppressive. It is therefore tempting to speculate that the
observed inverse correlation between H. pylori colonization and
allergic asthma is mechanistically linked to neonatally acquired
immune tolerance to the bacterium (see The Beneﬁcial Effects
of H. pylori on Allergic and Chronic Inﬂammatory Disorders are
Mediated by Tregs and Tolerogenic DCs).
H. PYLORI PROTECTS AGAINST INFLAMMATORY BOWEL
DISEASE
THE PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE
Other immune system disorders for which inverse associations
with H. pylori have been examined are the inﬂammatory bowel
diseases (IBDs), chronic inﬂammatory conditions of unknown
etiology of the gastrointestinal (GI) tract. Twomain types of IBDs–
Crohn’s disease and ulcerative colitis are distinguished based on
the affected GI region and transmural involvement. Crohn’s dis-
ease is characterized by transmural inﬂammation of the bowel
preferentially involving the terminal ileum and right colon. Ulcer-
ative colitis manifests as a chronic inﬂammatory condition of the
colonic mucosa; in its most limited form it may be restricted to
the distal rectum, while the entire colon is involved in its most
advanced form. The main symptoms of both IBDs are diarrhea,
abdominal pain, and weight loss. Standard medications for both
IBDs include salicylates, corticosteroids, and other immunomod-
ulators; surgery is required for the treatment of bowel stenosis,
abscesses, and internal ﬁstulas in Crohn’s disease patients. Cura-
tive treatment is currently not possible as the etiology of both IBDs
is unclear.
In healthy individuals, intestinal mucosal homeostasis is con-
trolled by FoxP3+CD4+ Tregs, which efﬁciently suppress path-
ogenic T-cell responses through IL-10 and TGF-β (Maloy et al.,
2003; Kamanaka et al., 2006; Li et al., 2007a). The failure of
regulatory networks to control excessive T-cell responses breaks
this equilibrium and leads to chronic inﬂammation. In patients
with ulcerative colitis, the intestinal production of IL-4 and IL-
13 cytokines is reminiscent of an atypical Th2 adaptive response
(Fuss et al., 1996), whereas Crohn’s disease patients present a Th1-
polarized cytokine proﬁle, with production of interferon gamma
(IFN-γ), tumor necrosis factor alpha (TNF-α), and IL-12 (Fuss
et al., 1996). In addition, both types of diseases are characterized
by the accumulation of IL-17-producing CD4+ T-cells, termed
Th17 cells (Annunziato et al., 2007). These cells differentiate from
naïve T-cells through the synergistic effects of IL-6 and TGF-β,
IL-1, and IL-21 (Veldhoen et al., 2006; Korn et al., 2007) and
require IL-23 for their maintenance and expansion (Ouyang et al.,
2008). Recent work has shown that IL-23 drives chronic intesti-
nal inﬂammation in a mouse model of colitis by directly targeting
T-cells, and induces their proliferation and accumulation in the
colon (Hue et al., 2006). IL-23 further favors the emergence of
an immunogenic IL-17A+IFN-γ+ double-positive CD4+ T-cell
subset (Hue et al., 2006; Ahern et al., 2010) and inhibits the differ-
entiation of FoxP3+ Treg cells (Kullberg et al., 2006; Ahern et al.,
2010), suggesting that the IL-23/Th17 axis is a major determinant
in the pathogenesis of IBD. The key role of IL-23 is also sup-
ported in humans, as increased expression of IL-23 is detected in
IBD patients and mutations in the IL23R gene increases suscepti-
bility to both Crohn’s disease and ulcerative colitis (Ahern et al.,
2010). IL-23 can also drive inﬂammation in the absence of T-cells.
In lymphocyte-deﬁcient Rag−/− mice, the development of colitis
following Helicobacter hepaticus infection or treatment with ago-
nistic anti-CD40 antibody depended on IL-23 (Hue et al., 2006;
Yen et al., 2006). This inﬂammationwas further attributed to an IL-
23-responsive innate lymphoid population that expresses IL23R,
Thy1 and RORγt, and secretes IL-17 and IFN-γ (Buonocore et al.,
2010). The detection of a similar innate lymphoid cell population
in the inﬂamed intestine of patients provided evidence for a func-
tional role of IL-23-responsive innate cells in the pathogenesis of
IBD (Buonocore et al., 2010).
HELICOBACTER INFECTION IS INVERSELY CORRELATED WITH IBD
Several epidemiological studies have examined a possible inverse
correlation between IBDs and Helicobacter infection. A Hungar-
ian study investigating 133 IBD patients (both Crohn’s and colitis
patients) and similar numbers of controls found a signiﬁcant
inverse association with H. pylori infection (Pronai et al., 2004);
whereas only 13% of IBD patients carried H. pylori, the rates
ranged from 39 to 67% in various control groups (Pronai et al.,
2004). This result was conﬁrmed in a Polish study examining 94
pediatric IBD patients (both types of IBD), which revealed a lower
H.pylori colonization rate inpatients compared tohealthy controls
(9.6 vs. 38.4%, p< 0.0001; Sladek et al., 2007). A recent meta-
analysis conducted by Luther et al. (2010) of 30 articles examining
such a possible link conﬁrmed that H. pylori infection may indeed
confer some level of protection against IBD,with only 27% of IBD
patients showing evidence of H. pylori infection compared to 41%
of patients in the control group. The authors caution, however,
that the heterogeneity among examined studies and the possibil-
ity of publication bias may limit the certainty of their ﬁndings. It is
therefore all the more interesting that the same group has provided
experimental evidence of protective effects of H. pylori infection
on Salmonella typhimurium-induced colitis. Upon co-infection
of both bacteria, H. pylori suppressed Salmonella-speciﬁc Th17
responses in the cecum, and reduced cecal inﬂammation caused by
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Salmonella infection (Higgins et al., 2011). The protective effects
were linked to increased levels of IL-10 in the mesenteric lymph
nodes of co-infected over Salmonella-only infected mice, suggest-
ing that this regulatory cytokine modulates the differentiation
and/or activity of Th17 cells (Higgins et al., 2011). The same group
has attributed the protective effects of H. pylori on colitis to the
bacteria’s chromosomalDNA,which appears to exhibit a high ratio
of immunoregulatory to immunostimulatory sequences (Luther
et al., 2011) and is by itself sufﬁcient to prevent sodium dextran
sulfate-induced colitis. In their experimental protocol, Luther et al.
(2011) treated mice with one orally administered dose of 20–50 μg
H. pylori DNA prior to subjecting them to an acute and a chronic
protocol of colitis induction; in both models, administration of
the DNA reduced the pathology and also attenuated other para-
meters of DSS-induced colitis such as bleeding and weight. The
protective properties of H. pylori DNA were attributed to inhibi-
tion of cytokine production by DC, which upon addition of the
DNA failed to produce type I interferon and IL-12 in response to
E. coli DNA (Luther et al., 2011).Whether H. pylori DNA is indeed
the relevant factor conferring protection against IBD in humans or
mice remains to be elucidated in more detail; in fact, data show-
ing protection by live infection in IBD models other than acute
Salmonella-induced colitis are currently not available.
H. PYLORI MAY PROTECT AGAINST OTHER T-CELL-DRIVEN
AUTO-IMMUNE DISEASES
Given the documented protective effects of H. pylori infection on
asthma and other allergic disease manifestations on the one hand,
and IBD on the other, the possibility has been raised that the
presence or absence of this infection may also inﬂuence the risk
of developing additional T-cell-driven immunological or meta-
bolic disorders (Blaser and Falkow, 2009). The incidence of auto-
immune diseases caused by the aberrant activation of aggressive
autoreactive T-cells, such as multiple sclerosis (MS) and type I
diabetes mellitus, has increased sharply in the second half of the
twentieth century (Bach, 2002), i.e., in the time frame in which H.
pylori has begun to disappear – at least in recent birth cohorts –
from human populations in most developed countries (Blaser and
Falkow, 2009). Socioeconomic conditions favoring lower H. pylori
transmission and infection rates, such as frequent use of antibi-
otics in childhood, small family size, and non-crowded housing
(Blaser and Falkow, 2009) have all also been found to be associ-
atedwith a higher prevalence of allergic and auto-immunediseases
(Bach, 2002). While a possible inverse correlation between H.
pylori infection and auto-immune diseases remains largely spec-
ulative at this point in time, it is tempting to postulate that the
same immunomodulatory and immunoregulatory mechanisms
protecting infected individuals from allergic asthma may also be
operative against excessive T-cell-driven auto-immune activation.
The pathogenesis of auto-immune diseases has been studied most
thoroughly in MS, an auto-immune disorder directed against the
myelin sheath of neuronal axons, causing demyelination and a
broad spectrum of CNS symptoms. In MS, as in IBD (see H. pylori
Protects Against Inﬂammatory Bowel Disease), the Th17 subset of
helper T-cells is thought to be the driving force behind the chronic
(neuro-) inﬂammation causing disease symptoms. It is nowwidely
accepted that Th17 cells, not Th1 cells as believed previously
(Gutcher and Becher, 2007), are the main encephalitogenic popu-
lation in auto-immuneneuro-inﬂammation in experimental auto-
immune encephalomyelitis (EAE), the standard mouse model of
MS. Pathogenic auto-immune Th17 cells are characterized by
the secretion of the cytokines IL-22, IL-21, IL-17A, IL-17F, and
GM–CSF (Littman and Rudensky, 2010). A recent study has
reported a dominant role for Th17-derived GM–CSF in auto-
immune CNS inﬂammation based on the evidence that autore-
active helper T-cells speciﬁcally lacking GM–CSF failed to initiate
neuro-inﬂammation despite expression of IL-17A and IFN-γ,
whereas GM–CSF secretion by Ifng−/−Il17a−/− helper T-cells was
sufﬁcient to induce EAE (Codarri et al., 2011).
Very little solid epidemiological data is available to date to sup-
port a protective effect of H. pylori on the development of MS.
One study has found an inverse correlation of H. pylori infection
with MS in the Japanese population (Li et al., 2007b), and some
studies point to a higher prevalence of MS in adults with a record
of having been afﬂictedwith asthma in childhood (Ponsonby et al.,
2006). In the study by Li et al. (2007b) examining 105 MS patients
and 85 healthy controls, H. pylori seropositivity was signiﬁcantly
lower in patients with conventional MS (22.6%) relative to the
healthy controls (42.4%). This result obviously remains to be con-
ﬁrmed in larger patient cohorts, and should also be experimentally
examined in the EAE model of MS. In EAE, CNS inﬂammation
and progressive paralysis of the tail and hind limbs is entirely
driven by myelin-speciﬁc auto-aggressive T-cells (Codarri et al.,
2011), and should therefore be susceptible to H. pylori-induced,
Treg-mediated immunoregulation. Other experimental models of
auto-immune disease, such as the non-obese diabetic model of
type I diabetes (Chaparro et al., 2006) may provide informative
results as well.
THE BENEFICIAL EFFECTS OF H. PYLORI ON ALLERGIC AND
CHRONIC INFLAMMATORY DISORDERS ARE MEDIATED BY
TREGS AND TOLEROGENIC DCs
TREGS PROMOTE H. PYLORI PERSISTENCE, LIMIT GASTRIC
INFECTION-ASSOCIATED IMMUNOPATHOLOGY AND PREVENT AIRWAY
HYPER-RESPONSIVENESS IN MICE
Numerous recent reports have implicated Tregs and DCs with
tolerogenic activity inmediating the systemic immunomodulatory
effects of H. pylori infection, both in human carriers, and in exper-
imentally infected animals. In a seminal study examining human
gastric T-cell responses to H. pylori infection, Robinson et al.
(2008) showed that patients with peptic ulcer disease exhibited
stronger Th1 and Th2 responses to H. pylori than asymptomatic
carriers; conversely, the latter group predominantly mounted Treg
responses to the infection. IL-10-expressingTregswereparticularly
abundant in the gastric mucosa of the normal carriers compared
to the peptic ulcer disease patients; interestingly, mucosal IL-
10 levels were directly correlated with bacterial densities, with
asymptomatic carriers showing high IL-10 expression receiving
the highest colonization scores and peptic ulcer disease patients
with low IL-10 expression receiving comparatively low coloniza-
tion scores (Robinson et al., 2008). In a similar study conducted by
Harris et al. (2008) the relatively mild gastritis typical of H. pylori-
infected children could also be linked to Treg-predominant T-cell
responses. Children with a mild form of gastritis exhibited higher
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gastric mucosal Treg numbers and higher levels of the regulatory
cytokines IL-10 and TGF-β than adults with more severe gastritis
(Harris et al., 2008). Evidence for a functional role for Tregs and
Treg-derived cytokines in promoting H. pylori persistence on the
one hand, and in mediating H. pylori-induced immunomodula-
tion on the other has been provided in experimental infection
models. The earliest such evidence came from IL-10−/− mice,
which are able to spontaneously clear Helicobacter infections, but
suffer from – at least temporarily – strongly enhanced Th1 medi-
ated gastritis (Ismail et al., 2003). The depletion of Tregs in mice
infected with Helicobacter at 6 weeks of age using a CD25-speciﬁc
antibody resulted in a strong reduction in colonization, and in
accelerated and enhanced gastritis (Sayi et al., 2011). The deple-
tion of Tregs in a genetic mouse model in which the diphtheria
toxin receptor is expressed under the Treg-speciﬁc foxp3 promoter
(foxp3-DTR-transgenic mouse) also resulted in clearance of the
infection and in severe gastritis, even accompanied by the devel-
opment of preneoplastic gastric lesions (Arnold et al., 2011b).Mice
whose CD4+ T-cells cannot respond to TGF-β due to transgenic
expression of a dominant-negative form of TGF-β receptor II also
develop strongly enhanced pathology and spontaneously reduce
bacterial burdens (Arnold et al., 2011b), indicating that TGF-β-
dependent inducible Tregs, but not TGF-β-independent natural
Tregs, are predominantly involved in maintaining persistence and
in mediating H. pylori-speciﬁc immunomodulation. Interestingly,
the systemic depletionof Tregs in the foxp3-DTR-transgenicmodel
improved the clearance of H. pylori by vaccinated mice, suggesting
that the efﬁcacy of an H. pylori vaccine is signiﬁcantly hampered
by the Treg-mediated suppression of protective effector T-cell
responses (Hitzler et al., 2011). The latest evidence for an impor-
tant role of Tregs in the immunomodulation conferring protection
against asthma was provided by the ﬁnding that the depletion of
Tregs abrogates asthma protection (Arnold et al., 2011a). Con-
versely, as mentioned above, puriﬁed Tregs alone were sufﬁcient
to transfer protection fromH. pylori-infected donors to uninfected
recipients (Arnold et al., 2011a). Whereas as few as 100’000 Tregs
isolated from neonatally infected donors were suppressive in the
asthma model, Tregs from uninfected or adult-infected mice failed
to confer protection (Arnold et al., 2011a). The selective suppres-
sivity of Tregs from neonatally infected mice can be attributed
to the fact that neonatal exposure to H. pylori induces immune
tolerance to the bacteria (Arnold et al., 2011b).
H. PYLORI RE-PROGRAM DCs TOWARD TOLEROGENICITY
In contrast to natural Tregs, which originate from the thymus,
inducible Tregs are generated in the periphery. Certain popula-
tions of poorly immunogenic DCs are believed to initiate and
maintain peripheral immune tolerance through the induction of
anergy, deletion of autoreactive T-cells and the instruction and
differentiation of inducible Tregs (Maldonado and von Andrian,
2010). Such tolerogenic DCs function by converting naive T-cells
into FoxP3+ Tregs through antigen presentation in the absence of
co-stimulatory signals or cytokines, either alone or in combination
with the production of soluble and membrane-bound tolerogenic
factors such as IL-10, TGF-β, retinoic acid, and programmed
death ligands (PD-Ls; Kretschmer et al., 2005; Maldonado and
von Andrian, 2010). DCs appear to indeed play a central role in
the induction and maintenance of H. pylori-speciﬁc immune tol-
erance (Figure 2). The depletion of DCs impairs vaccine-induced
protective immunity to a similar degree as the depletion of Tregs
in the same model (Hitzler et al., 2011). In experimental infection
models using adult-infected mice, the depletion of DCs improves
the control of the infection and strongly enhances gastric T-cell
inﬁltration and chronic gastritis (Hitzler et al., 2011). DCs iso-
lated from the mesenteric lymph nodes of neonatally infected,
tolerant mice exhibit tolerogenic properties ex vivo, i.e., they act
as poor inducers of Th1 or Th17 cells, and excellent inducers of
Tregs (Oertli et al., 2012). The depletion of DCs from neona-
tally infected, tolerant mice is consequently sufﬁcient to break
tolerance (Oertli et al., 2012). Whereas a functional role for DCs
in balancing tolerance and immunity in Helicobacter infection
is thus well established, the underlying mechanism is much less
thoroughly understood. Evidence from in vitro infection of bone-
marrow-derived DCs suggests that H. pylori possesses the ability
to profoundly re-program DCs toward tolerogenicity (Figure 2;
Kao et al., 2010; Oertli et al., 2012). DCs that have been exposed to
H. pylori fail to undergo maturation upon stimulation with E. coli
LPS; the IL-12 secretion and up-regulation of the co-stimulatory
molecules CD80, CD86, and CD40 that are hallmarks of LPS-
matured DCs are prevented by the infection (Figure 2; Oertli et al.,
2012). H. pylori-exposed DCs further efﬁciently induce FoxP3
expression in co-cultured naive T-cells in a TGF-β-dependent
manner, but fail to prime Th1 or Th17 cells (Kao et al., 2010;
Oertli et al., 2012). The ability of H. pylori to re-program DCs in
such a manner requires direct contact (Oertli et al., 2012), but is
independent of the virulence factor CagA (Kao et al., 2010).
THE TOLEROGENICITY OF DCs REQUIRES THE SYNTHESIS,
PROCESSING, AND SECRETION OF INTERLEUKIN-18
The tolerogenic activity of DCs requires the DC-intrinsic expres-
sion and processing of IL-18 (Figure 2), as demonstrated by
the inability of IL-18−/− DCs to induce FoxP3 expression in
co-cultured T-cells and the failure of IL-18 receptor-deﬁcient (IL-
18R−/−) T-cells to convert to FoxP3+ Tregs upon co-culturing
with H. pylori-infected wild type DCs (Oertli et al., 2012). Indeed,
IL-18−/− aswell as IL-18R−/− mice exhibit signiﬁcantly lower Treg
numbers in their mesenteric lymph nodes than wild type mice
under conditions of Helicobacter infection, and generate stronger
Th17 responses and develop more severe infection-associated
immunopathology (Oertli et al., 2012). CD4+CD25+ cells iso-
lated from infected IL-18−/− or IL-18R−/− donors fail to prevent
allergen-induced asthma, indicating that not only the differenti-
ation, but also the suppressive activity of Tregs depends on IL-18
signaling (Oertli et al., 2012). The currentmodel thus assumes that
the availability of IL-18 dictates whether naive T-cells co-cultured
with DCs differentiate into Th1, Th17, or Treg cells; whereas Th1
and Treg differentiation depend crucially on IL-18, Th17 cells
develop under conditions where IL-18 is lacking (Figure 2). The
results obtained in the H. pylori model are reminiscent of the
hypersusceptibility of IL-18−/− animals toward experimentally
induced colitis, which has been attributed to the lack of Nlrp6
inﬂammasome activation (Elinav et al., 2011). Which nod-like
receptors are involved in the innate immune recognition of H.
pylori leading to caspase-1 activation and IL-18processing remains
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FIGURE 2 | Schematic representation of the effects of H. pylori exposure
on DCs and the DC/T-cell interaction. Exposure to H. pylori induces
semi-mature DCs with high expression of MHC class II, but only low to
moderate expression of the co-stimulatory molecules CD40, CD80, and
CD86, and of the cytokine IL-12. In contrast, IL-10 is made in large quantities
by H. pylori -experienced DCs. Inﬂammasome activation by H. pylori through
as yet uncharacterized cytoplasmic nod-like receptors (NLRs) leads to
caspase-1 activation and the processing and secretion of IL-1β and IL-18. IL-1β
promotesTh17 differentiation, whereas IL-18 is required for Th1 andTreg
differentiation. H. pylori -experienced DCs actively induce the conversion of
naive T-cells to FoxP3+ Tregs in a process that requires IL-18, TGF-β, and
possibly IL-10. In contrast, H. pylori -experienced DCs are poor inducers of
Th17 andTh1 differentiation. The documented lack of H. pylori TLR ligands in
conjunction with efﬁcient inﬂammasome activation by the bacteria suggests
that the relative availability of pro-IL-1β (low level expression due to lack of
transcriptional activation) and pro-IL-18 (high levels due to constitutive
expression) for caspase-1 processing may dictate the outcome of the
DC/T-cell interaction.
to be determined. It is interesting to note in this context that H.
pylori lacks many TLR ligands shared by other gram-negative,
pathogenic bacteria. H. pylori ﬂagellin is a poor ligand of TLR5
(Gewirtz et al., 2004) due to mutations in the TLR5 recognition
site of the N-terminal D1 domain of ﬂagellin (Andersen-Nissen
et al., 2005). The bacterium’s LPS consists predominantly of the
tetra-acylated lipid A variety, which is known to exhibit 1000-
fold reduced bioactivity as compared to E. coli LPS (Moran et al.,
1997). While H. pylori harbors TLR2 ligands (Rad et al., 2009;
Sayi et al., 2011), these exhibit predominantly anti-inﬂammatory
properties in vivo (Sayi et al., 2011). The combined results imply
that the lack of (pro-inﬂammatory) TLR signaling in conjunc-
tion with high level inﬂammasome activation and IL-18 secretion
may favor Treg over Th17 differentiation during H. pylori infec-
tion. Our recent ﬁnding that addition of E. coli LPS can reverse
the tolerogenic effects of H. pylori on DCs (Oertli et al., 2012)
lends further support to this model. LPS is a strong inducer of
IL-1β, which in turn is required for Th17 polarization (Figure 2).
The relative availability of IL-1β and IL-18, which is inﬂuenced
by TLR-/Myd88- and NF-κB-dependent transcriptional activa-
tion of IL-1β expression (IL-18, in contrast, is preformed and
stored in granules, and not subject to extensive transcriptional
regulation), thus dictates whether Tregs or Th17 cells are pref-
erentially induced. In the context of H. pylori exposure of DCs,
IL-18 is produced in copious amounts due to efﬁcient inﬂam-
masome activation; in contrast, due to the concomitant lack of
TLR-mediated transcriptional activation, IL-1β is not available
for caspase-1-mediated processing, leading to the preferential dif-
ferentiation of naive T-cells into Tregs as opposed to Th17 cells
(Figure 2).
As Th17 cells have been implicated in adaptive immunity to H.
pylori infection (DeLyria et al., 2009;Velin et al., 2009;Hitzler et al.,
2011), the preferential induction of Tregs over Th17 cells may have
conferred a selective advantage to the bacteria in the 60000 years
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of co-evolution of H. pylori with its human host (Moodley et al.,
2009) and explains why infected individuals with strong gastric
Treg, but weak T-effector responses show the highest levels of col-
onization and the least severe gastric pathology (Robinson et al.,
2008).Anonly recently recognizedbystander effect of the strongH.
pylori-speciﬁc Treg induction is cross-suppression of allergen- or
autoantigen-speciﬁc T-cell responses (Arnold et al., 2011a), which
results in the above-discussed protective effects against asthma and
other allergies, as well as against IBDs.
CONCLUSION AND PERSPECTIVES
Two avenues of active research in the Helicobacter ﬁeld will likely
beneﬁt most from integrating the concepts outlined here into
current models and strategies; on the one hand, it is obvious
that H. pylori – or at least its tolerance-promoting properties –
should be harnessed for the development of new preventive or
therapeutic strategies in the treatment of asthma and other aller-
gies, and of IBDs. Whether an infection-independent strategy
sometimes referred to as “tolerizing vaccination” will work in this
context remains to be seen. On the other hand, vaccine develop-
ment efforts directed at eradicating H. pylori (therapeutically or
prophylactically) must take into account the need to overcome
the immunomodulatory properties of this infection if sterilizing
immunity is to be achieved. Finally, itwill be interesting to compare
the strategies that H. pylori has evolved to establish and maintain
persistent infection to those exploited by other chronic bacteria
such asmycobacteria and Salmonella. Overriding the immune eva-
sion and – modulation strategies of persistent bacterial infections
is a crucial ﬁrst step in breaking the asymptomatic carrier state
and in successfully interrupting the transmission cycle that per-
petuates the worldwide public health problems associated with
these persistent infections.
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